Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Trial of ACX-362E for the Treatment of Clostridium difficile Infection (CDI)

Trial Profile

A Phase I Trial of ACX-362E for the Treatment of Clostridium difficile Infection (CDI)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2019

At a glance

  • Drugs ACX 362E (Primary)
  • Indications Clostridium difficile infections
  • Focus Adverse reactions; First in man
  • Sponsors Acurx Pharmaceuticals
  • Most Recent Events

    • 16 Jan 2019 According to an Acurx Pharmaceuticals media release, ACX-362E has recently entered this trial.
    • 16 Jan 2019 Status changed from planning to recruiting, according to an Acurx Pharmaceuticals media release.
    • 26 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top